Cardiovascular Signal: TRT vs Supraphysiological AAS
MI/stroke data, the TRAVERSE trial, and high-dose androgen harm
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
~5,200 participants (TRAVERSE). The written rationale for this grade is still being prepared.
- FDA
- Testosterone is FDA-approved for hypogonadism; supraphysiological/illicit use is not
- WADA
- Prohibited (S1 Anabolic Agents)
Reference only. Not medical advice.
What can go wrong
For monitored replacement, TRAVERSE provides reassurance on heart attack and stroke while noting increased atrial fibrillation, pulmonary embolism, and acute kidney injury - risks warranting monitoring. For supraphysiological/illicit use, the risk profile is materially worse: documented cardiomyopathy, accelerated atherosclerosis from HDL suppression, polycythemia-related clotting, and sudden cardiac death.
This is something to take to a clinician. The Atlas can tell you what is known about cardiovascular signal: trt vs supraphysiological aas in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
The cardiovascular story of androgens splits sharply by dose. For physiological replacement in hypogonadal men, the TRAVERSE trial (Lincoff et al., NEJM 2023; ~5,200 men at elevated cardiovascular risk) found testosterone non-inferior to placebo for major adverse cardiac events - easing years of concern from earlier observational signals and an FDA-mandated study. TRAVERSE did, however, flag more atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone arm. By contrast, supraphysiological AAS use (megadoses many times replacement) is associated with adverse cardiac remodeling, sharply lowered HDL, accelerated atherosclerosis, and the sudden cardiac deaths reported in bodybuilders (Baggish et al., Circulation 2017). Conflating the two is a common and dangerous error.
The data say 'replacement looks cardiac-neutral; megadosing does not.'
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Physiological testosterone restores normal androgen levels; TRAVERSE suggests this is broadly cardiac-neutral for major events in hypogonadal men, though with some signal for AFib and thromboembolism. Supraphysiological doses, by contrast, drive left-ventricular hypertrophy, suppress HDL while raising LDL, raise hematocrit and clotting risk, and may be directly pro-arrhythmic - a constellation implicated in coronary disease and sudden death.
Safety in detail
Testosterone therapy requires physician evaluation and monitoring. Supraphysiological androgen use carries documented cardiovascular risks that physiological replacement does not. Self-administration without medical oversight carries documented health risks.
- Replacement: broadly MACE-neutral per TRAVERSE
- Replacement: increased AFib, PE, acute kidney injury signal
- Supraphysiological: cardiomyopathy and low HDL
- Supraphysiological: sudden cardiac death risk
Replacement is not the same as a cycle
This entry's central point is the gulf between physiological replacement and supraphysiological/anabolic dosing. TRAVERSE (NEJM, 2023) found no increase in major adverse cardiac events from physiological testosterone replacement in hypogonadal men at elevated cardiovascular risk. That reassurance does NOT extend to the supraphysiological doses used in bodybuilding, where adverse cardiovascular remodeling and events are documented.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Hematocrit
- Lipid panel
- Blood pressure
- Cardiac rhythm assessment
- PSA per age guidance
What people get wrong
Often said'TRAVERSE proves steroids are safe for the heart'
ActuallyTRAVERSE studied physiological replacement, not the supraphysiological doses used in bodybuilding. Its reassurance does not transfer; Baggish 2017 documents cardiac harm at high doses.
Often said'TRT has no cardiovascular downside at all'
ActuallyTRAVERSE itself flagged more atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone arm - replacement is broadly MACE-neutral, not free of all cardiovascular effects.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Replacement trial
- TRAVERSE, NEJM 2023, ~5,200 men
- MACE result
- Non-inferior to placebo
- TRAVERSE caveats
- More AFib, PE, acute kidney injury
- Supraphysiological
- Adverse remodeling, low HDL, SCD risk
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Cardiovascular Signal: TRT vs Supraphysiological AAS. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Lincoff et al. (TRAVERSE)2023
In ~5,200 hypogonadal men at high cardiovascular risk, testosterone was non-inferior to placebo for MACE; more AFib, PE, and acute kidney injury observed (NEJM)
Baggish et al.2017
Long-term supraphysiological AAS users showed reduced LV systolic and diastolic function vs non-using weightlifters (Circulation)